Atrial Fibrillation – Regeneron R7508-CVA-2393

Profound Research is enrolling an Atrial Fibrillation study that is assessing an investigational medication to see if they can reduce blood clotting without increasing the risk of bleeding in patients with Atrial Fibrillation.

To be eligible to participate, you must:

• Be at least 18 years of age
• Be diagnosed with Atrial Fibrillation or Atrial Flutter within the last year

Additional criteria apply.

Qualified participants will receive:

• Study-related care and study medication at no cost
• Financial compensation for time and travel expenses